Randomized, Double Blind, Placebo Controlled, Single IV Dose Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials
| City: |
|
Evanston |
| State: |
|
Illinois |
| Zip Code: |
|
60201 |
| Conditions: |
|
Major Depressive Disorder |
| Purpose: |
|
The purpose of this study is to determine whether GLYX-13 reduces depression score in
patients with treatment-resistant depression.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- diagnosis of major depressive disorder consistent with DSM-IV-TR
- current episode greater than 8 weeks in duration
- Hamilton Depression score >/- 21
- less than 25% reduction in depression during current episode assessed by ATRQ
Exclusion Criteria:
- Axis diagnosis of other psychiatric disorders
- Experiencing hallucinations, delusions, other psychotic symptomatology
- ECT during current episode
|
| NCT ID: |
|
NCT01234558 |
| Primary Contact: |
|
Study Director
Ronald M Burch, MD, PhD
Naurex, Inc
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Evanston, Illinois 60201
United States
There is no listed contact information for this specific location.
Site Status: N/A |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 22, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|